All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in symptomatic deep vein thrombosis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).
1 finding from 1 review
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Thrombocytopenia · patients with active cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health related quality of life · patients with active cancer with venous thromboembolism
1 finding from 1 review
All‐cause mortality · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Recurrent VTE · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis may leads to lower recurrent VTE compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Major GI bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in major GI bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Major upper GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Major lower GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major lower GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Major non‐GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Minor bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis probably leads to higher minor bleeding compared with low molecular weight heparin secondary prophylaxis (moderate certainty).
1 finding from 1 review
Minor GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Minor upper GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes minor upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review